Overview

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genmab
Collaborator:
BioNTech SE
Treatments:
Carboplatin
Gemcitabine
Paclitaxel
Pembrolizumab